Eli Lilly (LLY)

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

You can't go wrong with either, but one has a key difference that gives it the edge.

You might regret ignoring these companies at current levels.

There is no end in sight for the company's incredible momentum.

The drug giant added to its immunotherapy portfolio.

Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns.

Eli Lilly's $2.875 billion Merida Biosciences deal expands its immunology pipeline, as strong GLP-1 growth continues while LLY shares trail the broader health care sector.

Vanguard offers broad exposure at 0.09% cost with 1.5% yield, while Simplify's active strategy returned 32.4% over one year but charges 0.51%.

The high-flying healthcare leader looks unstoppable right now.

Hardly for the first time recently, the company is making a pricey acquisition.

The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

Eli Lilly is the leader in the GLP-1 space, but the company can't rest on its laurels.

Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space.

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that mos...

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...

Eli Lilly trades at $1,175 per share and has stayed right on track with the overall market, gaining 15.4% over the last six months. At the same time, the S&P...

Veeva Systems (NYSE:VEEV) reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded the company’s guidance. Management highlighted record CRM performance, broad commercial-cloud moment

New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.

Eli Lilly and Co. shares are trading lower Wednesday, pulling back from last week's record high despite positive real-world data on Zepbound.

Eli Lilly looks like a strong long-term investment thanks to its booming obesity drugs and Alzheimer's treatment, and to Billionaire Ken Griffin's investment.

VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.